KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables Refunds (2023 - 2025)

Sarepta Therapeutics has reported Receivables Refunds over the past 3 years, most recently at $14.3 million for Q3 2025.

  • Quarterly results put Receivables Refunds at $14.3 million for Q3 2025, up 25.2% from a year ago — trailing twelve months through Sep 2025 was $14.3 million (up 25.2% YoY), and the annual figure for FY2024 was $13.1 million, up 91.37%.
  • Receivables Refunds for Q3 2025 was $14.3 million at Sarepta Therapeutics, up from $7.2 million in the prior quarter.
  • Over the last five years, Receivables Refunds for SRPT hit a ceiling of $14.3 million in Q3 2025 and a floor of $6.9 million in Q4 2023.
  • Median Receivables Refunds over the past 3 years was $8.4 million (2024), compared with a mean of $9.8 million.
  • Biggest five-year swings in Receivables Refunds: skyrocketed 91.37% in 2024 and later decreased 13.92% in 2025.
  • Sarepta Therapeutics' Receivables Refunds stood at $6.9 million in 2023, then surged by 91.37% to $13.1 million in 2024, then grew by 8.89% to $14.3 million in 2025.
  • The last three reported values for Receivables Refunds were $14.3 million (Q3 2025), $7.2 million (Q2 2025), and $7.0 million (Q1 2025) per Business Quant data.